EA201892153A1 - Конденсированные пентациклические производные имидазола в качестве модуляторов активности tnf - Google Patents
Конденсированные пентациклические производные имидазола в качестве модуляторов активности tnfInfo
- Publication number
- EA201892153A1 EA201892153A1 EA201892153A EA201892153A EA201892153A1 EA 201892153 A1 EA201892153 A1 EA 201892153A1 EA 201892153 A EA201892153 A EA 201892153A EA 201892153 A EA201892153 A EA 201892153A EA 201892153 A1 EA201892153 A1 EA 201892153A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- disorders
- imidazole
- condensed pentacyclic
- tnf activity
- activity modulators
- Prior art date
Links
- 230000000694 effects Effects 0.000 title abstract 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical class C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 102000057041 human TNF Human genes 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 230000003040 nociceptive effect Effects 0.000 abstract 1
- 230000000771 oncological effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16163571 | 2016-04-01 | ||
| PCT/EP2017/057765 WO2017167993A1 (en) | 2016-04-01 | 2017-03-31 | Fused pentacyclic imidazole derivatives as modulators of tnf activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201892153A1 true EA201892153A1 (ru) | 2019-04-30 |
Family
ID=55650321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201892153A EA201892153A1 (ru) | 2016-04-01 | 2017-03-31 | Конденсированные пентациклические производные имидазола в качестве модуляторов активности tnf |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10669286B2 (enExample) |
| EP (1) | EP3436459B1 (enExample) |
| JP (1) | JP6968092B2 (enExample) |
| CN (1) | CN109195969B (enExample) |
| BR (1) | BR112018069936A2 (enExample) |
| CA (1) | CA3019026A1 (enExample) |
| EA (1) | EA201892153A1 (enExample) |
| WO (1) | WO2017167993A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201510758D0 (en) | 2015-06-18 | 2015-08-05 | Ucb Biopharma Sprl | Novel TNFa structure for use in therapy |
| HK1252623A1 (zh) | 2015-08-03 | 2019-05-31 | Bristol-Myers Squibb Company | 可用作TNFα调节剂的杂环化合物 |
| MA47106A (fr) | 2016-12-21 | 2019-10-30 | Amgen Inc | Formulations d'anticorps anti-tnf alpha |
| GB201621907D0 (en) | 2016-12-21 | 2017-02-01 | Ucb Biopharma Sprl And Sanofi | Antibody epitope |
| CN108948034B (zh) * | 2018-06-05 | 2019-09-13 | 河南大学 | 一种色满桥环异吲哚酮及其制备方法 |
| CN113227097B (zh) * | 2018-10-24 | 2023-09-08 | Ucb生物制药有限责任公司 | 作为tnf活性调节剂的稠合五环咪唑衍生物 |
| WO2024129763A1 (en) * | 2022-12-13 | 2024-06-20 | Forward Therapeutics, Inc. | MODULATORS OF TNF-α ACTIVITY |
| WO2024148191A1 (en) * | 2023-01-05 | 2024-07-11 | Forward Therapeutics, Inc. | MODULATORS OF TNF-α ACTIVITY |
| TW202513567A (zh) * | 2023-06-09 | 2025-04-01 | 大陸商上海翰森生物醫藥科技有限公司 | 五環類衍生物抑制劑、其製備方法與應用 |
| WO2025038927A1 (en) * | 2023-08-16 | 2025-02-20 | Raythera, Inc. | Modulators of tnf alpha activity and uses thereof |
| WO2025212627A1 (en) * | 2024-04-03 | 2025-10-09 | Forward Therapeutics, Inc. | Modulators of tnf-alpha activity |
| WO2025218735A1 (zh) * | 2024-04-17 | 2025-10-23 | 上海翰森生物医药科技有限公司 | 五环类衍生物抑制剂、其制备方法和应用 |
| WO2025255096A1 (en) * | 2024-06-03 | 2025-12-11 | Dana-Farber Cancer Institute, Inc. | Cycloalkyl and heterocyclic modulators of tnf activity |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2517281A1 (en) | 2003-03-10 | 2004-10-14 | Pfizer Inc. | Phosphate/sulfate ester compounds and pharmaceutical compositions for inhibiting protein interacting nima (pin1) |
| TW200615273A (en) * | 2004-11-10 | 2006-05-16 | Nicholas Piramal India Ltd | Fused tricyclic compounds as inhibitors of tumor necrosis factor-alpha |
| DE102008030206A1 (de) | 2008-06-25 | 2009-12-31 | Bayer Schering Pharma Aktiengesellschaft | 3-Cyanoalky- und 3-Hydroxyalkyl-Indole und ihre Verwendung |
| AR088728A1 (es) | 2011-03-25 | 2014-07-02 | Bristol Myers Squibb Co | Moduladores de lxr como prodroga de imidazol |
| JP5977344B2 (ja) | 2011-06-20 | 2016-08-24 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | ジャイレースおよびトポイソメラーゼ阻害剤のリン酸エステル |
| ES2675583T3 (es) * | 2012-06-11 | 2018-07-11 | Ucb Biopharma Sprl | Bencimidazoles moduladores de TNF-alfa |
| GB201212513D0 (en) | 2012-07-13 | 2012-08-29 | Ucb Pharma Sa | Therapeutic agents |
| BR112015000675B1 (pt) * | 2012-07-13 | 2022-07-12 | UCB Biopharma SRL | Derivados de imidazopiridina como moduladores da atividade de tnf |
| GB201321729D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321730D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321728D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| SG11201701796XA (en) | 2014-10-03 | 2017-04-27 | Ucb Biopharma Sprl | Fused pentacyclic imidazole derivatives |
-
2017
- 2017-03-31 US US16/086,418 patent/US10669286B2/en active Active
- 2017-03-31 EA EA201892153A patent/EA201892153A1/ru unknown
- 2017-03-31 EP EP17714783.2A patent/EP3436459B1/en active Active
- 2017-03-31 BR BR112018069936A patent/BR112018069936A2/pt not_active Application Discontinuation
- 2017-03-31 WO PCT/EP2017/057765 patent/WO2017167993A1/en not_active Ceased
- 2017-03-31 JP JP2018551351A patent/JP6968092B2/ja active Active
- 2017-03-31 CA CA3019026A patent/CA3019026A1/en not_active Abandoned
- 2017-03-31 CN CN201780033199.XA patent/CN109195969B/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP6968092B2 (ja) | 2021-11-17 |
| JP2019512535A (ja) | 2019-05-16 |
| US10669286B2 (en) | 2020-06-02 |
| US20190119302A1 (en) | 2019-04-25 |
| CN109195969B (zh) | 2021-12-21 |
| EP3436459B1 (en) | 2021-08-25 |
| WO2017167993A1 (en) | 2017-10-05 |
| CA3019026A1 (en) | 2017-10-05 |
| EP3436459A1 (en) | 2019-02-06 |
| CN109195969A (zh) | 2019-01-11 |
| BR112018069936A2 (pt) | 2019-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201892153A1 (ru) | Конденсированные пентациклические производные имидазола в качестве модуляторов активности tnf | |
| EA201892142A1 (ru) | Конденсированные пентациклические производные имидазола в качестве модуляторов активности tnf | |
| EA201992407A1 (ru) | Конденсированные пентациклические производные имидазола в качестве модуляторов активности tnf | |
| EA201790734A1 (ru) | Конденсированные пентациклические производные имидазола | |
| EA201892144A1 (ru) | Конденсированные гексациклические производные имидазола в качестве модуляторов активности tnf | |
| EA201792688A1 (ru) | Производные бензоксазинона и его аналоги в качестве модуляторов активности tnf | |
| EA201792047A1 (ru) | Новые соединения | |
| BR112016012990A2 (pt) | Derivados de imidazol tricíclicos fundidos como moduladores de atividade de tnf | |
| EA201401350A1 (ru) | Бензимидазолы, модулирующие tnf-альфа | |
| EA201500133A1 (ru) | Производные имидазопиразина в качестве модуляторов активности tnf | |
| EA201500130A1 (ru) | Производные имидазопиридина в качестве модуляторов активности tnf | |
| SA518391624B1 (ar) | Ror- منظمات جاما | |
| EA201692177A1 (ru) | Соединения и композиции в качестве агонистов toll-подобного рецептора 7 | |
| EA201590850A1 (ru) | Трициклические конденсированные производные тиофена как ингибиторы jak | |
| EA201590930A1 (ru) | Лекарственные формы руксолитиниба с замедленным высвобождением | |
| BR112016012261A2 (pt) | Derivados de tetra-hidroimidazopiridina como moduladores de atividade de tnf | |
| BR112016011483A2 (pt) | Derivados de imidazotriazina como moduladores de atividade de tnf | |
| EA201792686A1 (ru) | Производные индазола в качестве модуляторов активности tnf | |
| EA202091020A1 (ru) | Замещенные имидазопиридинамиды и их применение | |
| EA201790519A1 (ru) | Терапевтические соединения в качестве ингибиторов рецептора орексина-1 | |
| BR112016012258A2 (pt) | Derivados de tetra-hidrobenzimidazol como moduladores de atividade de tnf | |
| EA201792687A1 (ru) | Конденсированные трициклические имидазопиразины в качестве модуляторов активности tnf | |
| PH12020550788A1 (en) | Compositions and methods for the treatment of metabolic conditions | |
| EA201891710A1 (ru) | Терапевтические соединения | |
| MX389724B (es) | Compuestos de fenil-2-hidroxi-acetilamino-2-metil-fenilo |